HSP90-IN-9
HSP90-IN-9 is a potent and selective HSP90 inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2).
For research use only. We do not sell to patients.
- CAS No.: 2765247-36-5
- Formula: C30H31N3O5
- Molecular Weight:513.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
HSP90 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
13.12 μM
Compound: A17
|
Cytotoxicity against human A549 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against human A549 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
| BEAS-2B | IC50 |
>50 μM
Compound: A17
|
Cytotoxicity against human BEAS-2B cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against human BEAS-2B cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
| BV-2 | IC50 |
10.34 μM
Compound: A17
|
Cytotoxicity against mouse BV-2 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against mouse BV-2 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
| HepG2 | IC50 |
17.45 μM
Compound: A17
|
Cytotoxicity against human HepG2 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
| MCF7 | IC50 |
34.09 μM
Compound: A17
|
Cytotoxicity against human MCF7 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
| NIH3T3 | IC50 |
21.33 μM
Compound: A17
|
Cytotoxicity against mouse NIH3T3 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against mouse NIH3T3 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
| RAW264.7 | IC50 |
17.05 μM
Compound: A17
|
Cytotoxicity against mouse RAW264.7 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
| THLE-2 | IC50 |
7.15 μM
Compound: A17
|
Cytotoxicity against human THLE-2 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
Cytotoxicity against human THLE-2 cell assessed as inhibition of cell growth after 24 hrs by MTT assay
|
[PMID: 35298171] |
HSP90-IN-9 (compound A17) (combined with FLC (2 µg/mL)) shows antifungal activities against the six FLC-resistant Candida albicans (C. albicans) strains (MIC80s of 0.125 µg/mL in strain 901, strain 632, strain 100; MIC80s of 0.25 µg/mL in strain 904, strain 103,strain311, respectively)[1].
HSP90-IN-9 (24 h) shows low toxic to human cancer cells, human normal cells and the macrophage lineage (IC50s is 13.12, 34.09, 17.45, 7.15, >50, 21.33, 17.05, 10.34 µM in A549, MCF-7, HEPG2, THLE-2, BEAS-2B, NIH-3T3, Raw264.7, BV-2 cells, respectively)[1].
HSP90-IN-9 (32 μg/mL (combined with FLC (32 μg/mL)), 24 h) inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC[1].
HSP90-IN-9 (C. albicans (strain 904), 48 h) displays a fungicidal effect in a dose-dependent manner[1].
HSP90-IN-9 (FLC + compound A17 (32 + 32 μg/mL)) recovers azole sensitivity in resistant C.albicans by down-regulating the expression of CYP51 (ERG11) efflux pump-related genes (CDR1 and CDR2)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, MCF-7, HEPG2, THLE-2, BEAS-2B, NIH-3T3, Raw264.7, BV-2 cells
-
Concentration:
-
Incubation Time:24 h
-
Result:Showed low toxic to human cancer cells, human normal cells and the macrophage lineage (IC50s of 13.12, 34.09, 17.45, 7.15, >50, 21.33, 17.05, 10.34 µM in A549, MCF-7, HEPG2, THLE-2, BEAS-2B, NIH-3T3, Raw264.7, BV-2 cells, respectively).
-
Cell Line:Azole-resistant strain 904
-
Concentration:32 μg/mL (combined with FLC (32 μg/mL))
-
Incubation Time:24 h
-
Result:Inhibited fungal biofilm formation and fungal morphological changes after being combined with FLC.
HSP90-IN-9 (A17 (10 mg/kg)+FLC (1 mg/kg); i.p.; once a day for 5 days) exhibits potent in vivo antifungal efficacy by reducing the colonization and dissemination of fungi in tissue[1].
Pharmacokinetic Parameters of HSP90-IN-9 in male Sprague-Dawley (SD) rats[1].
| dose (mg/kg) | T1/2 (h) | C0 (ng/mL) | AUC(0-t) (h*ng/mL) | AUC(0-∞) (h*ng/mL) | Vz (L/kg) | Cl (mL/min/kg) | MRT(0-∞) (h) |
| 10 mg/kg | 1.26±0.31 | 4752.50±44.54 | 3005.15±35.59 | 3028.95±54.14 | 11.25±3.69 | 101.77±1.96 | 1.12±0.07 |
male Sprague-Dawley (SD) rats; 10 mg/kg; i.v.[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:male Sprague-Dawley (SD) rats[1]
-
Dosage:10 mg/kg
-
Administration:i.v.
-
Result:Exhibited moderate pharmacokinetic properties in SD rats.
-
Animal Model:female SD rats, 160-180 g (IFI rat model)[1]
-
Dosage:10 mg/kg, A17 (10 mg/kg)+FLC (1 mg/kg)
-
Administration:i.p., once a day, 5 days
-
Result:Exhibited potent in vivo antifungal efficacy by reducing the colonization and dissemination of fungi in tissue.
Chemical Information
-
CAS No. 2765247-36-5
-
Molecular Weight 513.58
-
Formula C30H31N3O5
-
SMILES
CCNC(C1=NOC(C2=C(C=C(C(C3=CC=C(C=C3)C)=C2)O)O)=C1C4=CC=C(C=C4)CN5CCOCC5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)